NIH R01 · 2025
Uncovering the dual anabolic and anti-catabolic effects of Pyk2 inhibition on bone mass
SUMMARY. Bone loss is accelerated in menopausal women, and more generally in both men and women with aging. Current anti-resorptive and osteoanabolic therapies are generally prescribed only after pronounced bone loss, and all can have adverse clinical effects. Dual-acting agents that are both osteoanabolic and anti-resorptive may offer novel approaches to increase bone mass. The Pyk2 tyrosine kinase is dual-acting, both decreasing osteoblast (OB) activity and increasing osteoclast (OC) resorption. Despite a similar increase in cortical microarchitecture in male and female Pyk2-/- mice, only females exhibit increased cancellous bone mass and mechanical properties, suggesting sex-specific…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.